机构名称：
¥ 1.0
J0177注射，Aflibercept HD，1 mg 4/1/2024 J0577注射，丁丙诺啡延长 - 重点（Brixadi），小于或等于治疗的7天4/1/2024 J0578 J0578 J0578 INTIMECTION，BUPRENORPHINE EXTEDEDED-RELEASE（BRIXEDED-REALEASE（BRIXAD）4/7/4/4/4/4/ Injection, daxibotulinumtoxina-lanm, 1 unit 4/1/2024 PA J0650 Injection, levothyroxine sodium, not otherwise specified, 10 mcg 4/1/2024 J0651 Injection, levothyroxine sodium (fresenius kabi) not therapeutically equivalent to J0650, 10 mcg 4/1/2024 J0652 Injection, levothyroxine sodium (hikma) not therapeutically equivalent to J0650, 10 mcg 4/1/2024 J1010 Injection, methylprednisolone acetate, 1 mg 4/1/2024 J1202 Miglustat, oral, 65 mg 4/1/2024 PA J1203 Injection, cipaglucosidase alfa-atga, 5 mg 4/1/2024 PA J1323 Injection, elranatamab-bcmm, 1 mg 4/1/2024 PA J2277 Injection, motixafortide, 0.25 mg 4/1/2024 J2782 Injection, avacincaptad pegol, 0.1 mg 4/1/2024 PA J2801 Injection, risperidone (rykindo), 0.5 mg 4/1/2024 J2919 Injection, methylprednisolone sodium succinate, 5 mg 4/1/2024 J3055 Injection, talquetamab-tgvs, 0.25 mg 4/1/2024 PA J3424 Injection, hydroxocobalamin, intravenous, 10 grams 4/1/2024 J7165 Injection, prothrombin复杂的浓缩液（人），balfaxar，per i.u.因子IX活动4/1/2024 J7354 CANTHARIDIN用于局部给药，0.7％，单位剂量施用器（3.2 mg）4/1/2024 PA
版权通知
主要关键词
相关文件推荐
